Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Solid pseudopapillary neoplasm of pancreas Indication Strategy Report 2026: CTNNB1, Trials and Deals
24 July 2026
2026 Solid pseudopapillary neoplasm of pancreas strategy: epidemiology, CTNNB1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pancreatic adenosquamous carcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
24 July 2026
2026 Pancreatic adenosquamous carcinoma strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Anal adenocarcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
24 July 2026
2026 Anal adenocarcinoma strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
HER2-positive colorectal cancer Indication Strategy Report 2026: HER2, Trials and Deals
24 July 2026
2026 HER2-positive colorectal cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Rectal cancer Indication Strategy Report 2026: EGFR, Trials and Deals
24 July 2026
2026 Rectal cancer strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Microsatellite instability-high colorectal cancer Indication Strategy Report 2026: PD-1, Trials and Deals
24 July 2026
2026 Microsatellite instability-high colorectal cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
EBV-positive gastric cancer Indication Strategy Report 2026: PD-1, Trials and Deals
24 July 2026
2026 EBV-positive gastric cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Diffuse gastric cancer Indication Strategy Report 2026: CDH1, Trials and Deals
24 July 2026
2026 Diffuse gastric cancer strategy: epidemiology, CDH1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Gastric signet ring cell carcinoma Indication Strategy Report 2026: CLDN18.2, Trials and Deals
24 July 2026
2026 Gastric signet ring cell carcinoma strategy: epidemiology, CLDN18.2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Vulvodynia Indication Strategy Report 2026: TRPV1, Trials and Deals
24 July 2026
2026 Vulvodynia strategy: epidemiology, TRPV1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Postpartum hemorrhage Indication Strategy Report 2026: Oxytocin receptor, Trials and Deals
24 July 2026
2026 Postpartum hemorrhage strategy: epidemiology, Oxytocin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Endometrial hyperplasia Indication Strategy Report 2026: Progesterone receptor, Trials and Deals
24 July 2026
2026 Endometrial hyperplasia strategy: epidemiology, Progesterone receptor biology, clinical competition, recent deals, unmet need and market attractiveness.